Incyte (INCY) Stock Price, Fundamentals & Analysis

What INCY does

Incyte (INCY) is a biopharmaceutical company that discovers, develops, and commercializes therapeutics in the United States, Europe, Canada, and Japan. Its portfolio includes treatments for blood and bone marrow disorders such as myelofibrosis and polycythemia vera, various cancers including chronic myeloid leukemia and biliary tract cancer, and inflammatory and autoimmune conditions.

Key numbers explained

• 124.64 USD is the current share price, representing the cost to buy one share on the US market.
• The trailing P/E ratio of 15.9 compares the share price to the last 12 months of earnings per share (7.85 USD); a lower number can suggest the stock is priced more conservatively relative to recent earnings.
• The forward P/E ratio of 14 uses expected future earnings, which can indicate how the market views the company’s growth prospects.
• 0% dividend yield and 0% share of earnings paid out as dividends mean the company does not currently distribute cash payments to shareholders.
• Beta of 0.77 suggests the stock has historically been less volatile than the overall market.
• Market cap of 25.26B USD places the company among large-cap stocks, and it is part of the S&P 500.
• Revenue growth of 37.7% year over year shows a strong top-line increase over the trailing 12 months.

Recent news

Recent headlines cover a broad range of topics relevant to biotech investing, from a general look at high-risk, high-reward “moonshot” stocks to a comparison of Incyte’s performance against other biotech companies. Other stories include regulatory catalyst watches and updates on specific drug programs, such as Incyte’s colorectal cancer research and its inflammation and autoimmunity portfolio presented at a European dermatology congress.

What to watch

Investors in stocks like Incyte typically monitor regulatory decisions from agencies such as the FDA, which can affect drug approvals and stock price. Broader factors include the overall direction of the healthcare and biotechnology sectors, clinical trial results for its drug pipeline, and how its financial metrics compare with peers like Merck & Co. (MRK) or Charles River Laboratories (CRL).